 As physicians in the United States, frequently we are told that you pick one. You're either a community doctor or you're an academic doctor and those buckets do not blend. And Kaiser Permanente has actually proved that statement to be wrong. I'm able to both think, encourage, learn, and study the next frontier while at the same time see my patients most days and provide that consistency in care. Clinical trials for oncology, more than any other fields, are vital. We function on the newest drugs. We function to improve our patient's survival. Until the day that cancer is cured, there's always room for improvement. And so therefore, we need clinical trials. Clinical trials assess the standard of care versus the new drugs that are coming down the pipeline. We try to select trials that has the highest impact. We have the children, the pediatric oncology group is very active in their clinical trials involvement in the greater community. We have the big three, prostate, lung, colon, and those are trials that impact the greatest number of patients. We also are involved in both radiation, neural oncology, women's cancer. So we really run the gamut in terms of our clinical trial engagement. Immunotherapy has really changed the world for a number of cancer patients. What we are trying to do conceptually is to mount an immune response against that cancer. So not only does the primary cancer shrink, but the hope is that you are left with a memory of that cancer immunologically and it can guard you against further incidents of cancer.